ABO incomplete antibodies for COVID-19

Abstract

Aim: To investigate whether the infectivity of severe acute respiratory syndrome coronavirus 2 was affected by covering and hiding blood group antigens with incomplete ABO antibodies. Methods: Incomplete antibodies were produced with using animal and human monoclonal/polyclonal antiA and AntiB antibodies. The aforementioned antibodies were converted to incomplete ABO antibodies through the utilization our patented method. The aforementioned incomplete antibodies were then incubated with the coronavirus in cell cultures. Moreover toxicity and effect of these two type incomplete antibodies were calculated. Results: Incomplete antibodies obtained from animals was highly toxic when encountered with severe acute respiratory syndrome coronavirus 2 in cell culture, the cells could not divide and the process could not be performed. However, the incomplete form of antibodies obtained from humans exhibited markedly reduced or even no toxicity when encountered with severe acute respiratory syndrome coronavirus 2. Even so, the study could be done with human originated incomplete antibodies, these incomplete antibodies were not effective against severe acute respiratory syndrome coronavirus 2, meaning they could not be used for treatment and prevention purposes for COVID-19. Conclusion: Human-derived incomplete antibodies did not completely eliminate the COVID-19 virus from infecting the cell, but slightly reduced it. Incomplete antibodies of animal origin are toxic to the cell. This study has shown that human-derived incomplete antibodies cannot currently be used as a treatment option for COVID-19, but since they are not toxic to the cell, and further studies can be carried out. The results of this study need to be supported by immunosuppressed animal studies.